Drug Trial Radar · NCT02750514
An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Mar 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
295
Actual
Start
May 9, 2016
Primary completion
Jan 29, 2020
Study completion Jan 29, 2020
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Apr 25, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether Nivolumab, in combination with other therapies, is effective in patients with advanced Non-Small Cell lung cancer
Conditions
- Advanced Cancer
Interventions
NivolumabBiological
Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.
DasatinibDrug
RelatlimabBiological
IpilimumabBiological
BMS-986205Drug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: From first dose to 2 years following last dose (up to 30 months)
- Duration of Response (DOR)Time frame: From first dose to 2 years following last dose (up to 30 months)
- Progression Free Survival Rate (PFSR) at 24 WeeksTime frame: From first dose to 24 weeks after first dose
Locations
50 sites in 8 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
University of Southern California (USC)
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
University of Californa, Los Angeles (UCLA)
Los Angeles, California
Hoag Memorial Hospital Presbyterian
Newport Beach, California
University of California San Diego
San Diego, California
University of Colorado Denver
Aurora, Colorado
Yale Cancer Center
New Haven, Connecticut
University of Kansas Cancer Center
Westwood, Kansas
University of Maryland - Marlene and Stewart Greenebaum Cancer Center
Baltimore, Maryland
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana Farber/Harvard Cancer Center
Boston, Massachusetts
University of Michigan Health System (UMHS) - University Hospital (University of Michigan Medical Ce
Ann Arbor, Michigan
Karmanos Cancer Institute
Detroit, Michigan
Washington University, The Center for Advanced Medicine
St Louis, Missouri
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Roswell Park Cancer Institute
Buffalo, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Univ of NC Shool of Medicine
Chapel Hill, North Carolina
The Ohio State University
Columbus, Ohio
Northwest Cancer Specialists
Portland, Oregon
Thomas Jefferson University
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
The West Clinic, P.C. d/b/a West Cancer Center
Germantown, Tennessee
Sarah Cannon Cancer Center
Nashville, Tennessee
Sammons Cancer Center (Uso)
Dallas, Texas
Texas Oncology, P.A.
Fort Worth, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
Us Oncology
Tyler, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
Virginia Cancer Specialists, PC
Fairfax, Virginia
University of Washington-Seattle Cancer Care Alliance
Seattle, Washington
Local Institution
Clayton, Victoria, Australia
Local Institution
Salzburg, Austria
Local Institution
Edmonton, Canada
Juravinski Cancer Centre, Hamilton Health Sciences-Mcmaster Univeristy's Faculty Of Health Sciences
Hamilton, Ontario, Canada
University Of Ottawa - The Ottawa Hospital Cancer centre
Ottawa, Ontario, Canada
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.